Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
基本信息
- 批准号:10178835
- 负责人:
- 金额:$ 51.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-15 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Acute Lung InjuryAgonistAzacitidineBindingBinding ProteinsBiochemicalBlood VesselsCadherinsCalciumCalcium SignalingCalmodulinCell NucleusComplexCpG dinucleotideDNADNA Methyltransferase InhibitorDNA Modification MethylasesDNMT3B geneDataDiseaseEdemaEndothelial CellsEndotheliumEpigenetic ProcessG-Protein-Coupled ReceptorsGene ExpressionGenesGenetic TranscriptionGoalsHomeostasisHomocysteineInflammatoryInvestigationKnock-outKnockout MiceLungMediatingMethyl-CpG-Binding Protein 2MethylationModelingMusNucleic Acid Regulatory SequencesOrangesPAR-1 ReceptorPhosphorylationPhosphotransferasesPromoter RegionsReceptor Protein-Tyrosine KinasesRegulationRepressionResolutionRoleS-AdenosylhomocysteineSeminalSepsisSignal TransductionTIE-2 ReceptorTLR4 geneTestingThrombinTransferaseVascular Endothelial CellVascular Permeabilitiesbasecadherin 5demethylationgenome wide methylationimaging approachinjury and repairlung injurylung repairmolecular imagingmortalitymouse modelnovelpreventprogramspromoterreceptor expressionrepairedresponserestorationseptic patientstherapeutic targettranscription factorvascular endothelial dysfunction
项目摘要
Optimal expression of endothelial-enriched tunica interna endothelial cell kinase (Tie2) and vascular endothelial
cadherin (VE-cad) in endothelial cells (ECs) is required to form restrictive endothelial barrier and to maintain
vascular homeostasis. Acute lung injury (ALI) is a complex inflammatory disease associated with increased lung
vascular permeability. Rapid reduction in the expression of Tie2 and VE-cad in ECs contributes to ALI. Studies
proposed in this application will test the central hypothesis that the calcium/calmodulin (Ca2+/CaM)-dependent
kinase CaMKKβ-mediated expression of the transcription factor Elf2 promotes the resolution of inflammatory
lung injury through the expression of Tie2 and VE-cad in ECs. This project was inspired by our seminal
observations that Camkkβ deficient (Camkkβ─/─) mice are unusually susceptible to LPS-induced lung injury and
that expression of both CaMKKβ and Elf2 is downregulated in lung endothelia from septic patients. We
discovered that CaMKKβ signaling downstream of TLR4 and PAR-1 (a GPCR) mediates EC expression of Elf2,
which in turn induces EC-specific transcription of the receptor tyrosine kinase Tie2, and VE-cad. In Camkkβ─/─
mice, the DNA methyltransferase inhibitor 5-azacytidine or expression of wild type (WT) but not kinase-defective
CaMKKβ, restored the expression of Tie2 and VE-cad. Genome-wide methylation analysis showed that the
gene encoding the transcription factor Elf2 was hyper-methylated in ECs of Camkkβ─/─ mice. Further, methyl-
CpG-binding protein 2 (MeCP2), which binds methylated-CpG and thereby represses transcription, was
associated with regulatory regions of the Elf2 gene in Camkkβ─/─ mice. Consistent with these findings, Elf2
expression was markedly reduced in ECs of Camkkβ─/─ mice. Interestingly, EC-specific deletion of either DNA
methyltransferase Dnmt3b (Dnmt3bEC─/─) or Mecp2 (Mecp2EC─/─) in mice, augmented Elf2 expression in ECs.
Importantly, in EC-specific Elf2 knockout (Elf2EC─/─) mice, expression of Tie2 and VE-cad was dramatically
reduced. Based on these novel findings, in Aim 1a, we will test the hypothesis that DNA methyl transferase
DNMT3b mediates methylation of Elf2-gene promoter in quiescent ECs and in Aim 1b, we will test the
hypothesis that the methyl CpG binding protein MeCP2, binds methylated-CpG in the promoter regions of the
Elf2 gene and inactivates Elf2 transcription. In Aim 2, we will test the hypothesis that CaMKKβ activated
downstream of TLR4 and/or PAR-1 mediates phosphorylation of MeCP2 residue S421, which in turn induces the
expression of Elf2 in ECs. In Aim 3, we will test the hypothesis that Elf2 activation is required for the optimal
expression of Tie2 and VE-cad in ECs and thus repair of the lung endothelial barrier. We will employ
biochemical, molecular, and imaging approaches to define the underlying mechanisms. Importantly, we will use
EC-restricted knockout mouse models (Dnmt3bEC─/─, Mecp2EC─/─, CamkkβEC─/─ and Elf2EC─/─) created by us to
accomplish the goals. Our hope is that these studies will identify therapeutic targets to reverse sepsis-induced
acute lung injury based on a deeper understanding of endogenous EC repair programs.
富内皮内膜内皮细胞激酶(Tie2)和血管内皮细胞的最佳表达
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHINNASWAMY TIRUPPATHI其他文献
CHINNASWAMY TIRUPPATHI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHINNASWAMY TIRUPPATHI', 18)}}的其他基金
Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
新型 E3 泛素连接酶 CHFR 调节内皮屏障完整性和先天免疫功能
- 批准号:
10488226 - 财政年份:2021
- 资助金额:
$ 51.97万 - 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
- 批准号:
10363718 - 财政年份:2021
- 资助金额:
$ 51.97万 - 项目类别:
Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
新型 E3 泛素连接酶 CHFR 调节内皮屏障完整性和先天免疫功能
- 批准号:
10297258 - 财政年份:2021
- 资助金额:
$ 51.97万 - 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
- 批准号:
10586059 - 财政年份:2021
- 资助金额:
$ 51.97万 - 项目类别:
Endothelial TAK1 Signaling and Resolution of Pulmonary Edema in Sepsis
脓毒症肺水肿的内皮 TAK1 信号转导和解决
- 批准号:
9535680 - 财政年份:2016
- 资助金额:
$ 51.97万 - 项目类别:
Endothelial Cell Deubiquitinase A20 Signals Repair of Lung Vascular Injury
内皮细胞去泛素酶 A20 发出肺血管损伤修复信号
- 批准号:
9301023 - 财政年份:2015
- 资助金额:
$ 51.97万 - 项目类别:
TRPM2 mediates neutrophil transendothelial migration and inflammation
TRPM2介导中性粒细胞跨内皮迁移和炎症
- 批准号:
9260918 - 财政年份:2015
- 资助金额:
$ 51.97万 - 项目类别:
Endothelial Cell Deubiquitinase A20 Signals Repair of Lung Vascular Injury
内皮细胞去泛素酶 A20 发出肺血管损伤修复信号
- 批准号:
9105412 - 财政年份:2015
- 资助金额:
$ 51.97万 - 项目类别:
Ca2+ Signaling, ICAM-1 Expression, and Lung Vascular Injury
Ca2 信号传导、ICAM-1 表达和肺血管损伤
- 批准号:
7457949 - 财政年份:2007
- 资助金额:
$ 51.97万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 51.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 51.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 51.97万 - 项目类别:














{{item.name}}会员




